ARCHIVES

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

This article is from The Cancer Letter archive.

Vol. 34 No. 9 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

In Brief: Hammer Hears A Claim for The $1 Million Wynder’s Theory On Japan’s Colon Cancer Rates: Hamburgers

March 19, 1982

NCI Programs: Institute Seeks White Papers On Technology

September 11, 1998

Protocols Approved By NCI

April 30, 2004

In Brief: Megastrol Acetate Still Under FDA Review; Mays Hired For NCI’s Technology Office

July 20, 1990

Abstracts Of Papers For Therapeutic Radiologists Meeting

November 7, 1975

Smokeless Tobacco Consensus Conference Slates in Health Risks

August 16, 1985